Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $182.6 million.

  • Beam Therapeutics' Total Current Liabilities rose 981.39% to $182.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.6 million, marking a year-over-year increase of 981.39%. This contributed to the annual value of $182.1 million for FY2024, which is 1143.14% down from last year.
  • Per Beam Therapeutics' latest filing, its Total Current Liabilities stood at $182.6 million for Q3 2025, which was up 981.39% from $174.1 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Total Current Liabilities peaked at $238.9 million during Q3 2022, and registered a low of $101.4 million during Q3 2021.
  • Its 5-year average for Total Current Liabilities is $184.5 million, with a median of $187.2 million in 2024.
  • In the last 5 years, Beam Therapeutics' Total Current Liabilities skyrocketed by 23046.21% in 2021 and then crashed by 2455.97% in 2024.
  • Quarter analysis of 5 years shows Beam Therapeutics' Total Current Liabilities stood at $213.4 million in 2021, then grew by 4.76% to $223.6 million in 2022, then decreased by 8.06% to $205.6 million in 2023, then fell by 11.43% to $182.1 million in 2024, then increased by 0.27% to $182.6 million in 2025.
  • Its last three reported values are $182.6 million in Q3 2025, $174.1 million for Q2 2025, and $141.5 million during Q1 2025.